Patents by Inventor Marc Kaestle

Marc Kaestle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20240011033
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Inventors: Sebastian Kreuz, Ludger Ickenstein, Marc Kaestle, Stephan Klee, Holger Klein, Thorsten Lamla, Benjamin Strobel
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230416738
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2020
    Publication date: December 28, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230407303
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 21, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF A FIBROTIC CONDITION
    Publication number: 20230049147
    Abstract: The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.
    Type: Application
    Filed: August 12, 2022
    Publication date: February 16, 2023
    Inventors: Jay FINE, Marc Kaestle, Janine Lamar, David Lamb, Meera Ramanujam, Sudha Visvanathan
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF
    Publication number: 20220213503
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: April 30, 2020
    Publication date: July 7, 2022
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle